Placebo News and Research

RSS

Evidence continues to grow about green tea's cancer prevention properties

Although scientists are reluctant to officially endorse green tea as a cancer prevention method, evidence continues to grow about its protective effects, including results of a new study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, which suggests some reduction in oral cancer.

5 Nov 2009

CHANTIX/CHAMPIX raises hope for quitting smoking

New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP).

5 Nov 2009

Green tea holds hope for prevention of oral cancer

Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center.

5 Nov 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

5 Nov 2009

Patient enrollment in three late-stage clinical trials completed

Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials.

5 Nov 2009

Imagenetix awarded U.S. patent for its 1-TDC drug candidate to treat periodontal disease

Imagenetix, Inc., announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.

5 Nov 2009

Green tea extract shows promise as cancer prevention agent for oral cancer, reveal researchers

5 Nov 2009

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.

4 Nov 2009

Osiris Therapeutics reports financial results for the third quarter of 2009

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its financial results for the third quarter of 2009.

4 Nov 2009

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

CPEX Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2009. For the quarter CPEX reported revenues of $5.0 million and a net loss of $872,000.

4 Nov 2009

Cost of ADHD clinical trials can be reduced by implementing Quotient ADHD System

BioBehavioral Diagnostics Company announced today that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009.

4 Nov 2009

iNO therapy for respiratory failure in premature babies does not improve long-term outcomes

Inhaled nitric oxide (iNO), a therapy used in the treatment of premature newborns with respiratory failure that had shown promising results in short-term studies, does not significantly improve long-term outcomes, according to a national study led by critical care researchers at the University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC.

4 Nov 2009

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected. In this clinical trial to be presented at the annual meeting of the American Association for the Study of Liver Diseases, researchers treated patients - both treatment naive and experienced patients - with a twice daily oral combination therapy of a nucleoside polymerase and protease inhibitor.

4 Nov 2009

XanGo Juice lowers levels of C-reactive protein in overweight and obese people

A new study published in Nutrition Journal indicates that XanGo- Juice, a market-leading, premium mangosteen beverage, has lowered levels of C-reactive protein (CRP) in overweight and obese people in a randomized, double-blind, placebo-controlled human trial.

4 Nov 2009

Coffee affects quality of daytime recovery sleep

Night-shift workers should avoid drinking coffee if they wish to improve their sleep, according to research published in the journal Sleep Medicine. A new study led by Julie Carrier, a Universit- de Montr-al psychology professor and a researcher at the affiliated H-pital du Sacr--C-ur Sleep Disorders Centre, has found the main byproduct of coffee, caffeine, interferes with sleep and this side-effect worsens as people age.

4 Nov 2009

Study: Estrogen replacement may help protect brain damage

Eighteen years ago this month the National Institutes of Health (NIH) announced that it would sponsor a landmark study to examine women and cardiovascular disease. Known as the Women's Health Initiative (WHI), the study enrolled more than 161,000 women.

4 Nov 2009

Aerovance enrolls 540 patients in Phase 2b Aerovant clinical trial

Aerovance Inc. today announced it has completed patient enrollment in a Phase 2b clinical trial of the inhaled dry powder formulation of Aerovant for the treatment of uncontrolled asthma. Top-line results are expected by the second quarter of 2010.

3 Nov 2009

Financial results for third-quarter 2009 announced by Combinatorx

CombinatoRx, Incorporated today reported financial results for the third quarter ended September 30, 2009.

3 Nov 2009

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.

3 Nov 2009

Want to quit smoking? Try a nicotine patch plus a nicotine lozenge

In a comparison of five different smoking cessation medications, a nicotine patch plus a nicotine lozenge appears most effective at helping smokers quit, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Nov 2009

Placebo News and Research

Evidence continues to grow about green tea's cancer prevention properties

CHANTIX/CHAMPIX raises hope for quitting smoking

Green tea holds hope for prevention of oral cancer

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Patient enrollment in three late-stage clinical trials completed

Imagenetix awarded U.S. patent for its 1-TDC drug candidate to treat periodontal disease

Green tea extract shows promise as cancer prevention agent for oral cancer, reveal researchers

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Osiris Therapeutics reports financial results for the third quarter of 2009

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

Cost of ADHD clinical trials can be reduced by implementing Quotient ADHD System

iNO therapy for respiratory failure in premature babies does not improve long-term outcomes

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

XanGo Juice lowers levels of C-reactive protein in overweight and obese people

Coffee affects quality of daytime recovery sleep

Study: Estrogen replacement may help protect brain damage

Aerovance enrolls 540 patients in Phase 2b Aerovant clinical trial

Financial results for third-quarter 2009 announced by Combinatorx

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Want to quit smoking? Try a nicotine patch plus a nicotine lozenge

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News